Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-0873 Patch · 1 trial · 1 indication
Following topical administration of MK-0873 or matching placebo patches once daily for 21 days, the number of participants with an adverse event of erythema was recorded. An adverse event is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
Participant blood samples were collected on Day 11 to determine the Cmax of MK-0873 following topical administration in healthy participants and participants with psoriasis
An adverse event is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
An adverse event is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
| Arm | Type | Description |
|---|---|---|
| Panel A - MK-0873 5.1 mg | EXPERIMENTAL | In Part I, healthy participants received skin patches containing nothing (plain patch), placebo, and various potencies of MK-0873 cream (0.05%, 0.5%, or 2%; yielding a dose of 5.1 mg of MK- 0873) once daily for 21 days. |
| Panel A - Placebo | PLACEBO_COMPARATOR | In Part I, healthy participants received skin patches containing nothing (plain patch) or placebo once daily for 10 days. |
| Panel B - MK-0873 25 mg | EXPERIMENTAL | In Part II, healthy participants received skin application of 0.5% MK-0873 cream (yielding a dose of 25 mg of MK- 0873) twice daily for 10 days. |
| Panel B - Placebo | PLACEBO_COMPARATOR | In Part II, healthy participants received skin application of placebo cream twice daily for 10 days. |
| Panel C - MK-0873 100 mg | EXPERIMENTAL | In Part II, healthy participants received skin application of 2% MK-0873 cream (yielding a dose of 100 mg of MK-0873) once daily for 10 days. |
| Panel C - Placebo | PLACEBO_COMPARATOR | In Part II, healthy participants received skin application of placebo cream once daily for 10 days. |
| Panel D - MK-0873 200 mg | EXPERIMENTAL | In Part II, healthy participants received skin application of 2% MK-0873 (yielding a dose of 100 mg of MK-0873) twice daily for 10 days. |
| Panel D - Placebo | PLACEBO_COMPARATOR | In Part II, healthy participants received skin application of placebo cream twice daily for 10 days. |
| Panel E and Extension - MK-0873 200 mg | EXPERIMENTAL | In Part III, participants with mild psoriasis received skin application of 2% MK-0873 cream (yielding a dose of 100 mg of MK-0873) twice daily for up to 28 days. |
| Panel E and Extension - Placebo | PLACEBO_COMPARATOR | In Part III, participants with mild psoriasis received skin application of placebo cream twice daily for up to 28 days. |
| Name | Type | Description |
|---|---|---|
| MK-0873 Patch | DRUG | MK-0873 skin patches containing 0.05%. 0.5%, or 2% MK-0873 |
| MK-0873 Cream | DRUG | MK-0873 cream containing 0.05%, 0.5%, or 2% MK-0873 |
| Placebo Patch | DRUG | Placebo patches matching MK-0873 0.05%, 0.5%, or 2% patches |
| Placebo Cream | DRUG | Placebo cream matching MK-0873 0.05%, 0.5%, or 2% |
| Plain patch | DRUG | Plain patch containing no MK-0873 or placebo |
Inclusion Criteria: Part I, II and III: * Female participants of reproductive potential must test negative for pregnancy and agree to use two acceptable methods of birth control; * In good general health; * Nonsmoker; Part III only: * Has diagnosis of plaque-type psoriasis, and has lesions cover...
MK-0873 is an investigational small molecule being studied for rheumatoid arthritis and plaque psoriasis. It is being developed by Merck & Company, Inc. (MRK). The drug has completed a Phase 2 trial in rheumatoid arthritis and a Phase 1 trial in plaque psoriasis, but it is not approved and remains in clinical development.
MK-0873 is being developed by Merck & Company, Inc., which trades under the ticker MRK. The company has sponsored clinical trials of the drug in rheumatoid arthritis and plaque psoriasis.
MK-0873 is in Phase 2 clinical development. A Phase 2 trial in rheumatoid arthritis has been completed, and a Phase 1 trial in plaque psoriasis has also been completed. The drug is investigational and not approved.
MK-0873 has been studied in two completed trials. NCT00132769 was a Phase 2, randomized, double-blind, placebo-controlled study in 106 rheumatoid arthritis patients. NCT01140061 was a Phase 1 study in 42 healthy participants and psoriasis participants.
MK-0873 is the code name used by Merck for this investigational compound. No alternative brand or generic names have been disclosed in the clinical trial records.